The short answer
The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. Mass compounding of these two drugs was lawful only because they sat on the FDA's drug shortage list — so removing them from the list removed the legal basis. The enforcement deadlines for compounders expired between February and May 2025.
Status checked July 13, 2026: neither drug is listed as in shortage. On April 30, 2026 the FDA went further and proposed to leave semaglutide, tirzepatide and liraglutide off the 503B bulks list, on a finding of no clinical need. That proposal is not final. Its comment period was extended and now closes July 30, 2026, so as of today the outcome is still open.
If you have been paying a couple of hundred dollars a month for a compounded vial and your provider has told you it is ending, none of this is your fault and it was not a scam you fell for. A legal switch flipped in Washington. Here is what actually happened, and what to do next.
Why the shortage made compounding legal in the first place
Under the Federal Food, Drug, and Cosmetic Act, a pharmacy generally may not compound a copy of an FDA-approved drug. That is the point of drug approval: the approved product has been tested, its manufacturing is inspected, and its dose is standardized.
The law carves out an exception. Sections 503A and 503B both permit compounding of what would otherwise be "essentially a copy" of an approved drug when that drug appears on the FDA drug shortage list. The exception exists so patients are not left with nothing when supply fails.
Demand for Ozempic, Wegovy, Mounjaro and Zepbound outran manufacturing capacity, and both active ingredients landed on the shortage list in 2022. That switched the exception on, and an industry appeared almost overnight: telehealth platforms, med spas and compounding pharmacies selling semaglutide and tirzepatide in multi-dose vials, typically for a few hundred dollars a month against a brand list price then above $1,000. It was lawful. It was also always temporary, and always contingent on a shortage that the manufacturers were spending billions to end.
The timeline
| Date | What the FDA did | What it meant in practice |
|---|---|---|
| 2022 | Semaglutide and tirzepatide injection added to the drug shortage list | The "essentially a copy" bar lifted; compounding of both became lawful |
| Oct 2, 2024 | FDA first declares the tirzepatide shortage resolved | Challenged by a compounders' trade group; FDA agrees to re-evaluate |
| Dec 19, 2024 | FDA reaffirms: tirzepatide shortage resolved | Legal basis for compounding tirzepatide ends |
| Feb 18, 2025 | End of FDA enforcement discretion for 503A pharmacies compounding tirzepatide | State-licensed pharmacies expected to stop |
| Feb 21, 2025 | FDA declares the semaglutide shortage resolved | Legal basis for compounding semaglutide ends |
| Mar 19, 2025 | End of enforcement discretion for 503B outsourcing facilities on tirzepatide | Large-scale tirzepatide compounding ends |
| Apr 22, 2025 | End of enforcement discretion for 503A pharmacies on semaglutide | A court declined to block the deadline; it stood |
| May 22, 2025 | End of enforcement discretion for 503B facilities on semaglutide | Large-scale semaglutide compounding ends |
| Apr 30, 2026 | FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need | Would close the remaining door for outsourcing facilities. Proposed, not final — the comment period was extended and closes July 30, 2026 |
503A vs 503B, in plain English
People say "compounding pharmacy" as if it were one thing. The law does not. The difference decides who could sell you a GLP-1 vial, and who still can.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | A state-licensed pharmacy compounding for one named patient at a time | A registered facility that may compound in batches, without patient names |
| Needs a prescription for a specific person? | Yes | Not necessarily — it can supply clinics and pharmacies |
| Follows FDA manufacturing standards (cGMP)? | No | Yes, and the FDA inspects |
| Products FDA-reviewed for safety and effectiveness? | No | No |
| Can it use bulk semaglutide or tirzepatide now? | Only in narrow, patient-specific circumstances a prescriber documents — not as a routine cheaper alternative | Not unless the substance is on the 503B bulks list or the drug is back in shortage. The FDA has proposed leaving all three GLP-1s off that list |
The line worth remembering: no compounded drug of any kind — 503A or 503B — has been reviewed by the FDA for safety, effectiveness or quality. Compounded GLP-1s are not FDA-approved products. That was true when they were cheap and legal, and it is true now.
What still legally exists is genuinely narrow. A prescriber documents that a specific patient cannot use the approved product — an allergy to an inactive ingredient, for example — and a 503A pharmacy compounds for that individual. "It costs less" and "I prefer the vial" are not that. Be sceptical of any site marketing "personalized" or "customized" semaglutide with an added vitamin as though it reopens the shortage-era door. Adding B12 to semaglutide does not make it a different drug, and the FDA has said so.
What this changed for the person paying
The compounded route disappeared at roughly the same time the manufacturers cut cash prices — which is not a coincidence. Two self-pay routes exist today, and both are dated below, because both change.
| Route | Price | Conditions to read carefully |
|---|---|---|
| Zepbound single-dose vials via LillyDirect (self-pay) | From $299/month (2.5 mg), $399 (5 mg), $449 (7.5 mg and above) | The $449 tier depends on refilling within 45 days of your last delivery. Outside that window, Lilly's published prices for the 12.5 mg and 15 mg vials are $849 and $1,049. "One month" means 28 days — four single-dose vials |
| Wegovy via NovoCare Pharmacy (self-pay) | $199/month for the first two fills at 0.25 mg and 0.5 mg; then $349/month for 0.25–2.4 mg, and $399/month for the 7.2 mg high dose | Novo states the $199 introductory offer runs through December 31, 2026, and that it may modify or cancel the program at any time |
Prices and program rules change without notice. Verify on the manufacturer's own page on the day you buy — not from any article, including this one. And whether your insurance covers a GLP-1 for weight (as opposed to for type 2 diabetes) is a decision your specific plan makes; no website can know it. Our cost & coverage estimator walks you through the exact questions to put to your plan and what the answers mean.
Disclosure: VidaBeacon may earn a commission from some care or product links elsewhere on this site. No manufacturer, pharmacy or telehealth company paid for or reviewed this article. Nothing here is a recommendation to buy, or to start, stop or change any medicine.
If your compounded supply is ending: the mistake that hurts people
Compounded semaglutide usually came as a multi-dose vial and a syringe. The approved products are pre-measured — a pen, or a single-dose vial holding a fixed amount. The numbers do not transfer.
The FDA has documented patients who, converting between milligrams, millilitres and "units" on an insulin syringe, injected five to twenty times the intended dose. Reported consequences included severe vomiting, dehydration, fainting, gallstones, pancreatitis and hospitalisation. Clinicians made the same arithmetic error. Compounded concentrations were never standardised, so a "unit" from one pharmacy did not mean a "unit" from another. This is the best-documented harm of the vial-and-syringe era, and it clusters at exactly the moment people switch products.
So, plainly: your prescriber sets your dose. Do not convert your own dose. Do not draw an "equivalent" amount from a leftover vial. Do not self-adjust — do not split, stretch, double or skip anything on your own, and do not double up after a missed dose. The dose escalation schedule printed on the FDA label is public information, and you can read what it says in our summary of the GLP-1 dosing schedule — but a label is a reference document describing what the manufacturer studied and the FDA approved. It is not an instruction to you. The transition from a compounded product to an approved one is exactly the moment to have a prescriber do the arithmetic deliberately.
Talk to your prescriber — and what to ask
Contact your prescriber (not a chat widget) if any of these apply:
- Your compounded supply has stopped or is about to, and you have no plan for what comes next.
- You have leftover compounded vials and are unsure what to do with them.
- You are being offered a "personalized" compounded version and cannot get a straight answer about which pharmacy makes it, or why the approved drug will not do.
Seek urgent medical care for signs of overdose or serious reaction: relentless vomiting, inability to keep fluids down, severe abdominal pain that bores through to the back (which can signal pancreatitis), fainting, or signs of severe dehydration.
Four questions worth writing down before the appointment:
- "I have been on a compounded product at roughly this amount. What is the correct starting dose of the approved product for me — and should I restart the escalation?"
- "Does my plan cover this for weight management, or only for diabetes? If it is denied, is there a prior authorisation or an appeal you would file?" Describe your situation accurately either way — an appeal built on a misstatement is an appeal that collapses.
- "If insurance says no, what is the honest self-pay cost through the manufacturer's own pharmacy, and can you send the prescription there?"
- "What should I watch for in the first month on the approved product?"
A note on telehealth: some platforms handled this transition honestly and some sold compounded product to the last legal minute. We do not recommend any particular one. When you evaluate a platform, ask who the prescriber is and whether you can speak to them; whether they dispense the FDA-approved product or a compounded one; whether they will name the pharmacy; and whether the price shown is the whole price, with no membership stacked on top. A platform that will not answer those in writing is telling you something. Our guide to evaluating online GLP-1 care covers the checks in more detail.
The honest bottom line
The shortage era produced a strange bargain: a real medicine, at a price people could pay, made by companies nobody was inspecting. It ended not because the drug stopped working but because the factories caught up — and the law was always written to end it at that moment. What is left is more expensive and better regulated. Whether that trade is fair is a policy argument, and the FDA's 503B proposal, still open for comment as of July 13, 2026, is where the next round of it happens. What is not arguable is that the moment of switching products is when people get hurt, and that it is almost entirely preventable by letting a prescriber do the maths.
More: how GLP-1 medications work, Zepbound vs Wegovy compared, protecting muscle on a GLP-1, and the glossary entry for semaglutide.
